Restart Life Sciences Corp.
NMLSF
$0.05
-$0.01-15.84%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 140.91% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 140.91% | -- | |||
| Cost of Revenue | 170.31% | -- | |||
| Gross Profit | 106.74% | -- | |||
| SG&A Expenses | 195.49% | 18.21% | |||
| Depreciation & Amortization | 124.14% | 866.67% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 186.64% | 44.54% | |||
| Operating Income | -206.31% | -0.90% | |||
| Income Before Tax | -205.25% | -107.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -205.25% | -107.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -205.25% | -107.89% | |||
| EBIT | -206.31% | -0.90% | |||
| EBITDA | -207.23% | -0.59% | |||
| EPS Basic | -187.80% | -41.38% | |||
| Normalized Basic EPS | -188.00% | 30.56% | |||
| EPS Diluted | -95.83% | -148.28% | |||
| Normalized Diluted EPS | -188.00% | 30.56% | |||
| Average Basic Shares Outstanding | 7.49% | 43.85% | |||
| Average Diluted Shares Outstanding | 7.49% | 43.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||